A practical reference on placebo-controlled trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-24. Anything still debated is marked as such rather than presented as settled.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Smashburger uses market research to determine where to open new restaurants, and the restaurant has favored opening new locations next to many major college campuses in the United States, sometimes opening shops directly on campus which are run by concessionaire companies like Compass Group and Aramark. It has also sought to open locations in casinos, in particular signing agreements in casinos in Las Vegas and in Oklahoma. It has also opened locations in high-traffic airports as well, partnering with HMSHost. A typical Smashburger location sees $3,000 to $5,000 in revenue during a mealtime rush, but its highest-volume restaurants can see $3 million to $5 million a year in sales. Ryan integrated ambiance, decor and music as a part of a larger customer experience. Restaurants are designed with specific decor, a prominently bright red color scheme, and customer flow. But, the restaurant does not have a model footprint and so each location can be tailored to the available space. Restaurant interiors are designed in a modern style with indirect lighting and decorated with locally produced photo murals. Customers order at a central counter and food is brought to them in stainless steel baskets. They are given silverware to eat with in place of plasticware. Restaurants are designed with a social feel in mind, and feature high tables and low tables, booths, and an outdoor patio. The company has a tailored music soundtrack for restaurants as well. An internal team designed and built the initial soundtracks around the restaurant's "Smash, sizzle, savor" theme.
These methods may be used repeatedly over large timespans to monitor changes in the environment. Camera traps have been found to be a useful tool for the detection and documentation of elusive species, nest predators and in the quantitative analysis of frugivory, seed dispersal and behaviour.
P7C3-A20 is a synthetic chemical compound belonging to the carbazole class. It was developed as a more potent analog of P7C3. It functions as an activator of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. P7C3-A20 exhibits proneurogenic and neuroprotective properties in preclinical models, crossing the blood-brain barrier and demonstrating efficacy in various models of brain injury and neurodegeneration. Research has investigated its potential to treat Alzheimer's disease, where it reversed pathological features and restored cognitive function in mice. As of 2025, P7C3-A20 remains an experimental compound with no established clinical use in humans.
transcytosis The transport of molecules across the interior of a cell, i.e. through the cytoplasm, especially a polarized cell such as an epithelial cell with contrasting apical and basal surfaces, thereby providing a spatially oriented transport system. Molecules undergoing transcytosis are usually contained within vesicles.
The Randle cycle is a biochemical mechanism involving the mutual inhibition of glucose and fatty acids in their oxidation and uptake in muscle and adipose tissue. The cycle controls fuel selection and adapts the substrate supply and demand in normal tissues. This cycle adds a nutrient-mediated fine tuning on top of the more coarse hormonal control on fuel metabolism. This adaptation to nutrient availability applies to the interaction between adipose tissue and muscle. Hormones that control adipose tissue lipolysis affect circulating concentrations of fatty acids; these in turn control the fuel selection in muscle. Mechanisms involved in the Randle Cycle include allosteric control, reversible phosphorylation and the expression of key enzymes. The energy balance from meals composed of differing macronutrient composition is identical, but the glucose and fat balances that contribute to the overall energy balance change reciprocally with meal composition.
Sources: en.wikipedia.org
In the 15th century, Cossack society was described as a federation of independent communities, which often formed local cavalry units and were entirely independent from neighboring states such as Poland, the Grand Duchy of Moscow, and the Crimean Khanate. There are confusing historical reports, according to Mykhailo Hrushevsky, that "the first mention of Cossacks dates back to the 14th century", although that seems indicative of people who were either Turkic or of undefined origin. Hrushevsky states that a deeper intuitive study of the evolution of the Cossacks indicates they may have descended from the long-forgotten Antes, or from groups from the Berlad territory of the Brodnici in present-day Romania, then a part of the Grand Duchy of Halych. There, the Cossacks may have served as self-defence formations, organized to defend against raids conducted by aggressive far-ranging tribes. The first international mention of Cossacks was in 1492, when Crimean Khan Meñli I Giray complained accusingly to Grand Duke of Lithuania Alexander Jagiellon that the Grand Duke's Cossack subjects from Kiev and Cherkasy had pillaged a Crimean Tatar ship. The duke ordered his "Ukrainian" (meaning borderland) officials to investigate, execute the guilty, and give their belongings to the Khan. Sometime in the 16th century, there appeared an old Ukrainian Ballad of Cossack Holota, about a Cossack near Kiliya. In the 16th century Cossack societies evolved into two independent territorial organizations, as well as other smaller, still-detached groups:
A GGT test is predominantly used as a diagnostic marker for liver disease. Elevated serum GGT activity can be found in diseases of the liver, biliary system, pancreas and kidneys. Latent elevations in GGT are typically seen in patients with chronic viral hepatitis infections often taking 12 months or more to present. Individual test results should always be interpreted using the reference range from the laboratory that performed the test, though example reference ranges are 15–85 IU/L for men, and 5–55 IU/L for women. GGT is similar to alkaline phosphatase (ALP) in detecting disease of the biliary tract. Indeed, the two markers correlate well, though there are conflicting data about whether GGT has better sensitivity. In general, ALP is still the first test for biliary disease. The main value of GGT is in verifying that ALP elevations are, in fact, due to biliary disease; ALP can also be increased in certain bone diseases, but GGT is not.
== Controversies over the hydrogen bond == Huggins believed that he had been the first to suggest the concept of the hydrogen bond, while he was a student under G. N. Lewis at the Chemical Laboratory of the University of California, Berkeley. According to his account, he wrote a thesis in 1919 in which the H-bond was introduced and applied to tautomerism in acetoacetic acid. Unfortunately, no hard copy of the thesis remains. The first extant publication of the H-bond was that of Wendell Latimer and Worth Rodebush in 1920, who cite Huggins' unpublished work in a footnote. (They were fellow scientists at the Chemical Laboratory.)
=== Secondary metabolites === Starfish produce a large number of secondary metabolites in the form of lipids, including steroidal derivatives of cholesterol, and fatty acid amides of sphingosine. The steroids are mostly saponins, known as asterosaponins, and their sulphated derivatives. They vary across species and are typically formed from up to six sugar molecules (usually glucose and galactose) connected by up to three glycosidic chains. Long-chain fatty acid amides of sphingosine occur frequently, with some having known biological activity. Starfish also contain various ceramides and a small number of alkaloids. These chemicals in the starfish may function in defence and communication. Some are feeding deterrents used by the starfish to discourage predation. Others are antifoulants and supplement the pedicellariae to prevent other organisms from settling on the starfish's aboral surface. Some are alarm pheromones and escape-eliciting chemicals, the release of which trigger responses in starfish of the same species, but often stimulate flight in potential prey. Research into the efficacy of these compounds for possible pharmacological or industrial use occurs worldwide.
Sources: en.wikipedia.org
=== Other uses in science and technology === Link (Mars), a rock outcrop Link or linking col, used in determining topographic prominence Telecommunications link, communication channel between two or more devices LINK, a spacecraft used in the Swift rescue mission
=== Pseudobulbar affect === In 2010, the FDA approved the combination drug dextromethorphan/quinidine under the brand name Nuedexta for the treatment of pseudobulbar affect (uncontrollable laughing/crying). Dextromethorphan is the active therapeutic agent in the combination; quinidine merely serves to inhibit the enzymatic degradation of dextromethorphan and thereby increase its circulating concentrations via inhibition of CYP2D6.
== Discovery == Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869. This same year, Édouard Laguesse named them after Langerhans. At first, there was a lot of controversy about what the Islets were made of and what they did. It appeared that all of the cells were the same within the Islet, but were histologically distinct from acini cells. Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells. He also determined that these granules were products of the metabolism of the cells in which they were contained. Michael Lane was the one to discover that alpha cells were histologically different than beta cells in 1907. Before the function of alpha cells was discovered, the function of their metabolic product, glucagon, was discovered. The discovery of the function of glucagon coincides with the discovery of the function of insulin. In 1921, Banting and Best were testing pancreatic extracts in dogs that had had their pancreas removed. They discovered that "insulin-induced hypoglycemia was preceded by a transient, rather mild hyperglycemia..." Murlin is credited with the discovery of glucagon because in 1923 they suggested that the early hyperglycemic effect observed by Banting and Best was due to "a contaminant with glucogenic properties that they also proposed to call 'glucagon,' or the mobilizer of glucose". In 1948, Sutherland and de Duve established that alpha cells in the pancreas were the source of glucagon.
== Plot == In 1982, French President François Mitterrand launches an anonymous international competition to design a monumental building on the historic axis linking the Louvre and the Arc de Triomphe. To general surprise, the winning entry comes not from one of the world's major architectural firms but from Johan Otto von Spreckelsen, a 53-year-old architecture teacher from Copenhagen who is unknown in France and has previously built only a handful of structures, including his own house and three small chapels. Overnight, von Spreckelsen is put in charge of the largest building project of the era, the Grande Arche de la Défense, which he affectionately calls his "cube". Determined to see the structure built exactly as he first envisioned it, he clashes repeatedly with the realities of French bureaucracy, represented chiefly by project administrator Jean-Louis Subileau, and with the pragmatic French architect Paul Andreu, who is brought in to oversee the building's technical execution. His uncompromising attachment to his original design, including a marble cladding that proves both structurally troublesome and hugely expensive, increasingly isolates him from the project's engineers and financiers. When the 1986 legislative elections bring a new, right-wing government to power in cohabitation with Mitterrand, the political backing that had protected von Spreckelsen evaporates. The film ends on a bleak note: worn down by the years-long conflict, von Spreckelsen dies before the Grande Arche is completed, which is inaugurated two years later.
==== Art ==== In 2008, the artist Roger Hiorns filled an abandoned waterproofed council flat in London with 75,000 liters of copper(II) sulfate water solution. The solution was left to crystallize for several weeks before the flat was drained, leaving crystal-covered walls, floors and ceilings. The work is titled Seizure. Since 2011, it has been on exhibition at the Yorkshire Sculpture Park.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.